≡ Risteys
R7

Documentation Changelog GitHub Contact & Feedback

Systemic lupus erythematosus, unspecified

DOIDEFOMESHSNOMED PheWeb

SLE_NOS

systemic lupus erythematosus: An autoimmune multi-organ disease typically associated with vasculopathy and autoantibody production. Most patients have antinuclear antibodies (ANA). The presence of anti-dsDNA or anti-Smith antibodies are highly-specific.

Endpoint definition

↥
FinnGen phenotype data

321302 individuals

diagram downward connector

Apply sex-specific rule None

321302

diagram downward connector

Check conditions None

321302

diagram downward connector
diagram bullet

Filter registries

Hospital Discharge: ICD-10 M32.9
Hospital discharge: ICD-9 $!$
Hospital discharge: ICD-8 $!$
Cause of death: ICD-10 M32.9
Cause of death: ICD-9 $!$
Cause of death: ICD-8 $!$

705

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, ICD version

Look only at ICD versions H.D: 10, 8, 9 ; C.O.D: 10, 8, 9

705

diagram downward connector

Check minimum number of events None

705

diagram downward connector

Include endpoints None

705

diagram downward connector
SLE_NOS

Extra metadata

First used in FinnGen datafreeze DF2
Parent code in ICD-10 M32
Name in latin Lupus erythematosus disseminatus non specificatus

Summary Statistics

↥

Key figures

All Female Male
Number of individuals 680 580 100
Unadjusted prevalence (%) 0.22 0.33 0.07
Mean age at first event (years) 47.01 46.32 51.01

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.02 1.90 [0.56, 6.41] 3.0e-1 49
15 years 0.01 1.48 [0.50, 4.33] 4.8e-1 22
5 years 0.00 4.25 [1.72, 10.54] 1.8e-3 15
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: SLE_NOS – Systemic lupus erythematosus, unspecified
GWS hits: 4

Survival analyses between endpoints

↥

Plot

before Systemic lupus erythematosus, unspecified
after Systemic lupus erythematosus, unspecified

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Systemic lupus erythematosus, unspecified

↥